Elevated Whole-Blood Manganese Levels in Adult Patients Prescribed "Manganese-Free" Home Parenteral Nutrition.
Parkinson disease
home parenteral nutrition
manganese
trace elements
Journal
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
ISSN: 1941-2452
Titre abrégé: Nutr Clin Pract
Pays: United States
ID NLM: 8606733
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
24
10
2019
medline:
26
8
2021
entrez:
24
10
2019
Statut:
ppublish
Résumé
Manganese toxicity can occur as a complication of home parenteral nutrition (HPN). Patients can present with Parkinson disease-like symptoms. Preparations of trace elements (TEs) in parenteral nutrition (PN) generally provide amounts in excess of requirements. Our previous review observed 60% of adult HPN patients had high whole-blood manganese levels. Multi-TE (MTE) solutions were subsequently removed from all HPN formulations in January 2015. The aim of this evaluation was to determine whole-blood concentrations of manganese in adult patients receiving HPN to establish whether levels are now maintained within the normal reference range. A retrospective review of whole-blood manganese levels in all patients receiving HPN between January 2018 and January 2019 from 1 hospital site was carried out. 100 patients were included in the review (59 female and 41 male). Normal whole-blood manganese levels (73-219 nmol/L) were observed in 70% of patients and elevated levels (>219 nmol/L) in 30% of patients. In the patients with elevated levels, 57% had not received manganese supplementation for at least 1 year prior to manganese being measured. Markers of cholestasis were similar between the 2 groups. Incidence of elevated whole-blood manganese concentrations in patients receiving HPN decreased from 60% to 30% upon discontinued use of an MTE solution. Elevated levels remain a concern despite patients being prescribed "manganese-free" PN. Patients receive this TE in amounts adequate to meet requirements through contamination and dietary intake alone, suggesting additional parenteral supplementation of manganese is not required.
Sections du résumé
BACKGROUND
BACKGROUND
Manganese toxicity can occur as a complication of home parenteral nutrition (HPN). Patients can present with Parkinson disease-like symptoms. Preparations of trace elements (TEs) in parenteral nutrition (PN) generally provide amounts in excess of requirements. Our previous review observed 60% of adult HPN patients had high whole-blood manganese levels. Multi-TE (MTE) solutions were subsequently removed from all HPN formulations in January 2015. The aim of this evaluation was to determine whole-blood concentrations of manganese in adult patients receiving HPN to establish whether levels are now maintained within the normal reference range.
METHODS
METHODS
A retrospective review of whole-blood manganese levels in all patients receiving HPN between January 2018 and January 2019 from 1 hospital site was carried out.
RESULTS
RESULTS
100 patients were included in the review (59 female and 41 male). Normal whole-blood manganese levels (73-219 nmol/L) were observed in 70% of patients and elevated levels (>219 nmol/L) in 30% of patients. In the patients with elevated levels, 57% had not received manganese supplementation for at least 1 year prior to manganese being measured. Markers of cholestasis were similar between the 2 groups.
CONCLUSIONS
CONCLUSIONS
Incidence of elevated whole-blood manganese concentrations in patients receiving HPN decreased from 60% to 30% upon discontinued use of an MTE solution. Elevated levels remain a concern despite patients being prescribed "manganese-free" PN. Patients receive this TE in amounts adequate to meet requirements through contamination and dietary intake alone, suggesting additional parenteral supplementation of manganese is not required.
Substances chimiques
Trace Elements
0
Manganese
42Z2K6ZL8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1142Informations de copyright
© 2019 American Society for Parenteral and Enteral Nutrition.
Références
Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. Mol Aspects Med. 2005;26(4-5):353-362.
Hardy G. Manganese in parenteral nutrition: who, when, and why should we supplement? Gastroenterology. 2009;137(5 suppl):S29-S35.
Shenkin A. Selenium in intravenous nutrition. Gastroenterology 2009; 137(5 suppl): S61-S69.
Bertinet D, Tinivella M, Balzola F.A, et al. Brain manganese deposition and blood levels in patient undergoing home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2000;24(4):223-227.
Fitzgerald K, Mikalunas V, Rubin H, McCarthy R, Vanagunas A, Criag R. Hypermanganesemia in patients receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1999;23(6):333-336.
Calne D, Chu N, Huang C, Lu C, Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology. 1994;44(9):1583-6.
Jin J, Saqui O, Allard J. Effect of discontinuation of manganese supplementation from home parenteral nutrition solutions on whole-blood levels and magnetic resonance imaging of the brain: a 5-year cohort study. JPEN J Parenter Enteral Nutr. 2018;42(1):164-170.
Livingstone C. Manganese provision in parenteral nutrition: an update. Nutr Clin Pract. 2017;33(3):404-418.
American Medical Association Department of Foods and Nutrition. Guidelines for essential trace element preparations for parenteral use: a statement by an expert panel. JAMA. 1979;241(19):2051-2054.
Staun M, Pironi L, Bozzetti F, et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr. 2009;28(4): 467-479.
Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491.
Osland EJ, Ali A, Isenring E, Ball P, Davis M, Gillanders L. Australasian Society for Parenteral and Enteral Nutrition guidelines for supplementation of trace elements during parenteral nutrition. Asia Pac J Clin Nutr. 2014; 23(4): 545-554.
Pironi L, Arends J, Bozzetti F, et al.; Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35(2):247-307.
Nair S, Jeffray C, Mountford C, Thompson N. PTH-212 High serum manganese levels in patients receiving long term total parenteral nutrition. Gut. 2015;64(suppl 1):A503.
Kurkus J, Alcock N, Shils M. Manganese content of large-volume parenteral nutrition solutions of nutrient additives. J Parenter Enteral Nutr. 1984;8(3):254-257.
Pluhator-Murton M, Fedorak R, Audette R, Marriage BJ, Yatscoff RW, Gramlich LM. Trace Element Contamination of total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1999;23(4):222-227.
Ayotte P, Plaa G. Hepatic subcellular distribution of manganese in manganese and manganese-bilirubin induced cholestasis. Biochem Pharmacol. 1985;3(21):3857-3865.
Wardle C, Forbes A, Roberts N, Jawhari A, Shenkin A. Hypermanganesemia in long-term intravenous nutrition and chronic liver disease. J Parenter Enteral Nutr. 1999;23(6):350-355.
Hope S-J, Daniel K, Gleason KL, Comber S, Nelson M, Powell JJ. Influence of tea drinking on manganese intake, manganese status and leucocyte expression of MnSOD and cytosolic aminopeptidase P. Eur J Clin Nutr. 2006;60(1):1-8.
Ali A, Murdoch A, Pascoe A, Murrell K, Kruger P. Can hypermanganesemia occur without cholestasis in patients receiving HPN. Nutrition 2008;24(5):508.
Stevens L, Rashid M. Manganese toxicity in patients on long term HPN therapy. JPEN J Parenter Enteral Nutr. 2008;23(2):197-198.